1. S-1 chemotherapy improves survival rate in pancreatic cancer patients.
2. Nab-paclitaxel earned approval for use in pancreatic cancer treatment.
3. Colorectal cancer with NRAS mutations is unlikely to benefit from panitumumab.
4. Capecitabine and bevacizumab are standar maintenance therapy in colorectal cancer.
5. Octreotide LA prolongs survival in midgut neuroendocrine tumors.
More Articles on Gastroenterology:
6 Things to Know About Infliximab as Ulcerative Colitis Treatment
5 Recent GI-Driven Center Openings & Plans
The Promise of Stem Cell Treatment for Crohn’s Disease & Ulcerative Colitis: Q&A With Dr. William Katkov
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.